Larimar Therapeutics/$LRMR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Larimar Therapeutics
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
Ticker
$LRMR
Sector
Primary listing
Employees
65
Headquarters
Website
LRMR Metrics
BasicAdvanced
$333M
-
-$1.56
0.94
-
Price and volume
Market cap
$333M
Beta
0.94
52-week high
$8.93
52-week low
$1.61
Average daily volume
3.8M
Financial strength
Current ratio
5.462
Quick ratio
5.235
Long term debt to equity
2.908
Total debt to equity
3.85
Profitability
EBITDA (TTM)
-108.21
Management effectiveness
Return on assets (TTM)
-35.04%
Return on equity (TTM)
-60.25%
Valuation
Price to book
2.08
Price to tangible book (TTM)
2.08
Price to free cash flow (TTM)
-2.685
Free cash flow yield (TTM)
-37.24%
Free cash flow per share (TTM)
-1.449
Growth
Earnings per share change (TTM)
37.26%
3-year earnings per share growth (CAGR)
-13.05%
What the Analysts think about LRMR
Analyst ratings (Buy, Hold, Sell) for Larimar Therapeutics stock.
LRMR Financial Performance
Revenues and expenses
LRMR Earnings Performance
Company profitability
LRMR News
AllArticlesVideos
Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMR
Business Wire3 days ago
Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMR
Business Wire2 weeks ago
Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – LRMR
Business Wire3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Larimar Therapeutics stock?
Larimar Therapeutics (LRMR) has a market cap of $333M as of November 03, 2025.
What is the P/E ratio for Larimar Therapeutics stock?
The price to earnings (P/E) ratio for Larimar Therapeutics (LRMR) stock is 0 as of November 03, 2025.
Does Larimar Therapeutics stock pay dividends?
No, Larimar Therapeutics (LRMR) stock does not pay dividends to its shareholders as of November 03, 2025.
When is the next Larimar Therapeutics dividend payment date?
Larimar Therapeutics (LRMR) stock does not pay dividends to its shareholders.
What is the beta indicator for Larimar Therapeutics?
Larimar Therapeutics (LRMR) has a beta rating of 0.94. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.